Official UK procurement notice
Herpes zoster, inactivated vaccine (2027)
Authority: Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency (Central government)
What is being bought
Published requirement descriptionThe provision of a vaccine to protect against herpes zoster, also known as shingles, to be used in the national immunisation programme.
This notice provides an indication to the market of UKHSA’s intention to enter into negotiations with GlaxoSmithKline (UK) Limited, with the objective of awarding a contract for the supply of the herpes zoster, inactivated (shingles) vaccine, in accordance with JCVI advice.
The lotProcurement structure
single lot · no lot value publishedLot #1Awarded
Procedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 13 Mar 2026, 08:02 GMT
- Last source update
- 13 Mar 2026, 08:02 GMT
- Authority reference
CM/PHV/27/C384964- FTS notice number
2026/S 000-022642- Latest notice
- Transparency notice (UK5)
- Delivery area
- Official registry OCID
ocds-h6vhtk-066916Find a Tender
- Why no open competition
- Single Suppliers Intellectual Property Exclusive Rights
- Published justification
The following conditions are met in relation to the public contract under Schedule 5, Paragraph 5 (a, b) of the Procurement Act 2023—
(a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and
(b)there are no reasonable alternatives to those goods, services or works.
- Risks
The below known unknown risks has been identified, which may require modification of the contract under paragraph 5 of Schedule 8 to the PA 2023 if one of the below identified risks materialise.
Risk 1:
The COVID-19 pandemic led to lockdown events, which disrupted the distribution and uptake of some national immunisation campaigns. The forecast delivery and stock requirements were substantially changed as a result. An ongoing risk is the materialisation of a UK health emergency or global pandemic, which may materialise in any given year.
How the risk may impact on the performance of the contract:
A health emergency or pandemic may materially affect the uptake of the herpes zoster, inactivated vaccine. Continued delivery of the vaccine within the original term of the contract could jeopardise stock management and effective use of vaccines before expiry.
Why is it not possible to address the potential impact of such risks?
UKHSA and suppliers cannot reasonably predict the occurrence of a pandemic. UKHSA cannot determine an effective delivery schedule and contract term which would be effective during a pandemic to mitigate the risk of reduced uptake.
Notice history
2 events · 1 release on Find a Tender · since 13 Mar 2026- Transparency notice published13 Mar 2026, 08:02 GMTUK5
- Contract signature expected6 Nov 2026, 23:59 GMTscheduled
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| GLAXOSMITHKLINE UK LIMITED1 Apr 2027 – 31 Mar 2029 · up to 31 Mar 2031Extensions: The Authority has the option to extend for a period or periods of up to an additional 24 months, subject to negotiation. | — | — | Standstill |
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- GlaxoSmithKline UK LimitedAwarded supplier
Official documents & specifications (1)
Official links; attachments are not copiedNotices published for this procedure
- Transparency notice Transparency notice on Find a Tender